Sharescart Research Club logo

Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹179 Cr.
Stock P/E
11
P/B
1.9
Current Price
₹89.2
Book Value
₹ 46.1
Face Value
10
52W High
₹205.1
52W Low
₹ 87.1
Dividend Yield
0%

Indo US Bio-Tech Overview

Company Name: Indo US Bio-Tech Ltd.

Ticker: INDOUS

1. Business Overview

Indo US Bio-Tech Ltd. operates within the agriculture sector. Based on its industry classification, the company is involved in agricultural activities, which could encompass a range of areas such as seeds, crop protection products, agricultural inputs, agri-biotechnology, or direct farming operations. The core business model likely involves the production, development, and/or sale of products and services essential for agricultural output, generating revenue through sales to farmers, distributors, or other agricultural enterprises.

2. Key Segments / Revenue Mix

Information on specific business segments and their respective contributions to revenue is not available from the provided data.

3. Industry & Positioning

The Indian agriculture industry is vast, complex, and crucial to the country's economy. It is characterized by a large number of small and marginal farmers, significant dependence on monsoons, and increasing adoption of modern farming techniques and inputs. The industry includes numerous players ranging from large multinational corporations to regional specialists in areas like seeds, fertilizers, pesticides, and farm machinery. Without specific operational details, Indo US Bio-Tech Ltd.'s exact positioning relative to peers (e.g., market share, specialization, geographic focus) cannot be determined. It likely competes with a mix of established domestic and international players, as well as smaller regional entities.

4. Competitive Advantage (Moat)

Without specific details on the company's operations, products, or market position, it is not possible to identify any definitive competitive advantages or "moats." Potential moats in the agriculture sector could include strong R&D capabilities in seed technology or biotechnology, an extensive and efficient distribution network, brand recognition among farmers, cost leadership in specific inputs, or high switching costs for specialized agricultural solutions. Whether Indo US Bio-Tech Ltd. possesses any of these is unknown.

5. Growth Drivers

Key factors that could drive growth for a company in the Indian agriculture sector over the next 3-5 years include:

Population Growth & Food Security: Increasing demand for food due to India's growing population.

Government Initiatives: Support schemes, subsidies, and policies aimed at boosting agricultural productivity and farmer income.

Technological Adoption: Rising adoption of advanced seeds, precision agriculture, and modern farming techniques.

Crop Diversification & Value Addition: Shift towards higher-value crops and processed agricultural products.

Improved Irrigation & Infrastructure: Investments in irrigation and supply chain infrastructure can enhance yields and market access.

6. Risks

Key business risks for a company in the Indian agriculture sector include:

Monsoon Dependence: Over-reliance on rainfall makes agricultural output highly vulnerable to adverse weather patterns.

Price Volatility: Fluctuations in commodity prices can significantly impact farmer incomes and demand for inputs.

Input Cost Inflation: Rising costs of fertilizers, pesticides, seeds, and labor can squeeze margins.

Regulatory Changes: Evolving government policies related to subsidies, pricing, trade, and environmental standards can affect operations.

Competition: Intense competition from domestic and international players.

Pest & Disease Outbreaks: Can lead to crop damage and reduced demand for specific products.

7. Management & Ownership

Information regarding the promoters, specific management team, their quality, or the detailed ownership structure of Indo US Bio-Tech Ltd. is not available from the provided data.

8. Outlook

Indo US Bio-Tech Ltd. operates in the fundamental and vital Indian agriculture sector, which presents inherent long-term growth opportunities driven by demographic trends and government focus on food security. However, the outlook for the company specifically is highly uncertain due to a complete lack of operational, financial, and strategic information.

A positive outlook would hinge on the company having a strong product portfolio (e.g., high-yielding seeds, effective crop protection), an efficient distribution network, sound financial management, and the ability to innovate and adapt to market demands and climate challenges. A less favorable outlook would arise from intense competition, susceptibility to agricultural risks like monsoon failure or price volatility, limited R&D capabilities, or poor execution.

Given the data scarcity, a detailed assessment is not possible; investors would require substantial additional information to form a conclusive view on its prospects.

Indo US Bio-Tech Share Price

Live · BSE / NSE · Inception: 2004
| |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Indo US Bio-Tech Quarterly Results

#(Fig in Cr.) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 22 16 25 22 24 33 31 31 23 26
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 22 16 25 22 24 34 31 31 23 26
Total Expenditure 18 15 21 17 18 29 25 27 19 23
Operating Profit 4 1 4 5 6 5 5 4 4 3
Interest 0 0 0 1 0 0 0 0 1 1
Depreciation 0 0 0 0 0 1 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 4 1 3 4 5 4 5 4 3 2
Provision for Tax 0 0 0 0 -0 0 0 0 0 0
Profit After Tax 4 1 3 4 5 4 5 3 3 2
Adjustments 0 0 0 0 -0 0 -0 0 0 0
Profit After Adjustments 4 1 3 4 5 4 5 3 3 2
Adjusted Earnings Per Share 1.8 0.3 1.6 2.2 2.5 1.8 2.3 1.7 1.5 1

Indo US Bio-Tech Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 20 19 25 30 35 40 40 50 62 73 104 111
Other Income 0 0 0 0 0 0 0 0 0 0 0 0
Total Income 20 19 25 30 36 40 40 50 62 73 104 111
Total Expenditure 19 19 23 27 32 36 35 43 52 62 85 94
Operating Profit 1 1 1 3 3 4 6 7 9 11 19 16
Interest 0 0 1 1 0 1 1 1 1 2 1 2
Depreciation 0 0 0 0 0 0 0 0 1 1 1 0
Exceptional Income / Expenses 0 0 0 0 -0 -0 0 0 0 0 0 0
Profit Before Tax 0 0 1 2 3 3 4 5 7 9 17 14
Provision for Tax -0 -0 0 1 1 0 -1 0 0 1 0 0
Profit After Tax 0 0 0 1 2 3 5 5 7 8 16 13
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 0 0 0 1 2 3 5 5 7 8 16 13
Adjusted Earnings Per Share 0.5 0.4 0.4 1.4 1.4 1.7 3.5 2.9 3.6 4.1 8.1 6.5

Indo US Bio-Tech Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 3 3 3 5 14 16 22 39 54 63 79
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 1 1 1 3 3 2 3 3
Other Non-Current Liabilities -0 -1 -0 0 1 1 1 1 0 1 -1
Total Current Liabilities 4 10 9 10 9 17 18 12 12 17 16
Total Liabilities 7 13 12 17 24 35 43 55 69 84 97
Fixed Assets 1 1 1 2 1 1 2 6 7 7 10
Other Non-Current Assets 0 0 0 0 1 1 3 3 2 4 0
Total Current Assets 6 12 11 15 21 32 38 47 60 73 87
Total Assets 7 13 12 17 24 35 43 55 69 84 97

Indo US Bio-Tech Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0 0 0 0 0 0 1
Cash Flow from Operating Activities 0 -3 0 -1 -3 -1 0 3 1 -5 1
Cash Flow from Investing Activities -0 -0 -0 0 -3 -1 -2 -5 -7 4 -1
Cash Flow from Financing Activities 0 3 0 1 6 2 1 2 6 1 -1
Net Cash Inflow / Outflow 0 0 -0 0 0 0 -0 -0 0 1 -1
Closing Cash & Cash Equivalent 0 0 0 0 0 0 0 0 0 1 0

Indo US Bio-Tech Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.48 0.35 0.39 1.41 1.43 1.74 3.5 2.86 3.61 4.12 8.11
CEPS(Rs) 0.59 0.49 0.53 1.56 1.6 1.89 3.67 3.09 4.02 4.51 8.66
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0.25
Book NAV/Share(Rs) 2.82 3.17 3.4 4.81 9.52 11.27 14.78 21.21 27.18 31.29 39.16
Core EBITDA Margin(%) 3.1 2.66 5.06 9.11 9.64 9.97 13.75 13.85 15.21 14.83 18.24
EBIT Margin(%) 2.96 2.43 4.73 9.32 9.03 9.43 13.24 13.37 13.91 14.17 17.35
Pre Tax Margin(%) 1.3 1.26 2.13 6.89 7.92 7.2 10.29 10.97 11.96 12.09 15.92
PAT Margin (%) 2.53 1.89 1.62 4.89 5.88 6.37 12.72 10.46 11.73 11.33 15.67
Cash Profit Margin (%) 3.12 2.62 2.22 5.41 6.56 6.91 13.34 11.31 13.06 12.43 16.72
ROA(%) 7.63 3.55 3.14 10.01 10.26 8.66 13.05 10.63 11.67 10.81 17.98
ROE(%) 19.83 11.69 11.74 34.36 22.21 16.74 26.87 17.34 15.51 14.08 23.03
ROCE(%) 13.92 7.39 14.24 27.84 20.35 16.65 18.3 15.86 14.62 14.42 21.15
Receivable days 30.8 66.23 79.35 86.57 92.79 137.87 207.92 164.93 133.85 109.71 59.84
Inventory Days 57.87 90.52 77.96 69.85 86.98 91.16 95.73 128.48 148.59 197.06 215.16
Payable days 46.8 86.01 79.05 63.91 54.15 418.37 0 -222.52 302.49 -53.89 597.69
PER(x) 0 0 0 0 24.41 12.29 3.87 11.81 29.43 53.94 18.15
Price/Book(x) 0 0 0 0 3.68 1.9 0.92 1.59 3.91 7.09 3.76
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0.17
EV/Net Sales(x) 0.16 0.32 0.26 0.33 1.61 0.99 0.78 1.48 3.64 6.29 2.98
EV/Core EBITDA(x) 4.57 10.08 4.82 3.39 16.56 9.96 5.6 10.45 23.84 41.2 16.21
Net Sales Growth(%) 32.22 -2.69 28.66 20.85 19.82 12.03 0.82 24.86 23.36 17.96 42.56
EBIT Growth(%) 78.43 -20.1 150.63 138.15 16.12 16.89 41.59 26.1 28.35 20.21 74.56
PAT Growth(%) 91.02 -27.42 10.06 265.83 44.11 21.38 101.13 2.73 38.25 13.96 97.15
EPS Growth(%) 52.53 -27.42 10.06 265.83 1.66 21.38 101.13 -18.39 26.4 13.96 97.15
Debt/Equity(x) 0.58 1.44 1.39 1.32 0.45 0.52 0.53 0.32 0.21 0.23 0.19
Current Ratio(x) 1.41 1.18 1.27 1.47 2.45 1.91 2.12 3.85 4.87 4.19 5.31
Quick Ratio(x) 0.46 0.65 0.67 0.87 1.21 1.36 1.46 1.94 2.68 1.22 0.98
Interest Cover(x) 1.78 2.08 1.82 3.83 8.1 4.24 4.5 5.57 7.15 6.79 12.09
Total Debt/Mcap(x) 0 0 0 0 0.12 0.28 0.58 0.2 0.05 0.03 0.05

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +42% +28% +21% +18%
Operating Profit CAGR +73% +39% +37% +34%
PAT CAGR +100% +47% +40%
Share Price CAGR -45% -6% +41%
ROE Average +23% +18% +19% +19%
ROCE Average +21% +17% +17% +17%

Indo US Bio-Tech Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 68.29 %
FII 0.18 %
DII (MF + Insurance) 0 %
Public (retail) 31.71 %
# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 70.1770.1770.1770.1770.1770.1770.1770.1770.1768.29
FII 0000000000.18
DII 0000000000
Public 29.8329.8329.8329.8329.8329.8329.8329.8329.8331.71
Others 0000000000
Total 100100100100100100100100100100

Indo US Bio-Tech Peer Comparison

Agriculture Edit Columns

Indo US Bio-Tech Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Indo US Bio-Tech Pros & Cons

Pros

  • Company has delivered good profit growth of 39% CAGR over last 5 years
  • Company is almost debt free.

Cons

  • Debtor days have increased from -53.89 to 597.69days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp